Skip to main content
. 2018 Nov 9;10(3):694–700. doi: 10.1039/c8sc04645j

Fig. 3. Reaction conditions and subsequent LC-MS analysis for (a) modification of recombinant PfRadA with DVP linkers 7, 8 and 9 resulted in covalently re-bridged conjugates 10, 11 and 12, and (b) bridging of trastuzumab Fab with 7, 8 and 9 resulted in the desired interchain bridged conjugates 13, 14 and 15.

Fig. 3